A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European LeukemiaNet (ELN) consensus process

British Journal of Haematology

Volumn 148, Issue 6, 2010, Pages 961-963

  Barosi, Giovanni ^a   Birgegard, Gunnar ^b   Finazzi, Guido ^c   Griesshammer, Martin ^d   Harrison, Claire ^e   Hasselbalch, Hans ^f   Kiladijan, Jean Jacques ^g   Lengfelder, Eva ^h   Mesa, Ruben ⁱ   Mc Mullin, Mary F ^j   Passamonti, Francesco ^k   Reilly, John T ^l   Vannucchi, Alessandro M ^m   Barbui, Tiziano ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c OSPEDALI RIUNITI   (Italy)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f ROSKILDE HOSPITAL   (Denmark)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ MAYO CLINIC   (United States)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k UNIVERSITY OF PAVIA   (Italy)

^l ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^m UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

Hydroxycarbamide; Intolerance; Polycythaemia vera; Primary myelofibrosis; Resistance

Indexed keywords

HYDROXYUREA; ANTINEOPLASTIC AGENT;

DISEASE COURSE; HEALTH SURVEY; HEMATOPOIESIS; HUMAN; LETTER; LEUKOCYTE COUNT; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUESTIONNAIRE; THROMBOCYTE; CONSENSUS DEVELOPMENT; DRUG RESISTANCE; NOMENCLATURE; PRIMARY MYELOFIBROSIS;

ANTINEOPLASTIC AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG RESISTANCE; HUMANS; HYDROXYUREA; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; TERMINOLOGY AS TOPIC;

EID: 77649227181     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08019.x     Document Type: Letter

References (10)

1. Barbui, T. Finazzi, G. (2005) When and how to treat essential thrombocythemia. New England Journal of Medicine, 353, 85 86.
2. Barosi, G., Bordessoule, D., Briere, J., Cervantes, F., Demory, J.L., Dupriez, B., Gisslinger, H., Griesshammer, M., Hasselbalch, H., Kusec, R., Le Bousse-Kerdiles, M.C., Liberato, N.L., Marchetti, M., Reilly, J.T., Thiele, J. European Myelofibrosis Network. (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 106, 2849 2853.
3. Barosi, G., Besses, C., Birgegard, G., Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J.T., Michiels, J.J. Barbui, T. (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia, 21, 277 280.
4. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829 4833.
5. Christoforidou, A., Pantelidou, D., Anastasiadis, A., Goutzouvelidis, A., Margaritis, D., Kotsianidis, I., Spanoudakis, E., Kaloutsi, V., Bourikas, G. Tsatalas, C. (2008) Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta Haematologica, 120, 195 198.
6. Dingli, D. Tefferi, A. (2005) A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leukemia & Lymphoma, 46, 641 650.
7. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E., Green, A.R. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33 45.
8. Kiladjian, J.J., Rain, J.D., Bernard, J.F., Briere, J., Chomienne, C. Fenaux, P. (2006) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 32, 417 421.
9. Randi, M.L., Ruzzon, E. Luzzatto, G. (2005) Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica, 90, 261 262.
10. Tefferi, A., Silverstein, M.N. Hoagland, H.C. (1995) Primary thrombocythemia. Seminars in Oncology, 22, 334 340.